Fraud & Abuse

Seton Hall Law’s Kathleen Boozang at Jotwell

Filed in Fraud & Abuse, Seton Hall Law by on September 10, 2014 0 Comments
Seton Hall Law’s Kathleen Boozang at Jotwell
Share

This week, Seton Hall Law’s Kathleen Boozang published a blog post at Jotwell reviewing Joseph Yockey’s article Choosing Governance in the FCPA Reform Debate, which was published in the Journal of Corporation Law. Dean Boozang writes: In the end, Yockey suggests a climate that is not unlike that of healthcare enforcement more generally: ‘Some firms likely […]

Share

Continue Reading »

No “Contracting Out” of Whistleblower Liability

No “Contracting Out” of Whistleblower Liability
Share

The recent Supreme Court decision in Lawson v. FMR LLC,  which dramatically expanded the reach of the Sarbanes Oxley Act, is interesting in a number of respects – not least because it involved what my colleague Professor Timothy Glynn describes as “employeeless employers.” The decision has obvious implications for the publicly traded sector in the […]

Share

Continue Reading »

Recent Research Regarding Potential Best Practices for Prescription Drug Monitoring Programs

Filed in Fraud & Abuse, New Jersey by on October 17, 2012 0 Comments
Recent Research Regarding Potential Best Practices for Prescription Drug Monitoring Programs
Share

As this blog has chronicled (see here and here), New Jersey has begun implementing the 2008 legislation that authorized creation of a Prescription Drug Monitoring Program (“PMP” or “PDMP”).  Although New Jersey’s PMP database has been collecting data for more than a year, the State has not yet issued implementing regulations to flesh out the […]

Share

Continue Reading »

Anti-Fraud Efforts Intensify, Broaden

Filed in Fraud & Abuse by on August 14, 2012 0 Comments
Anti-Fraud Efforts Intensify, Broaden
Share

Over the last few weeks, the fight against healthcare fraud has prominently been in the headlines. First, late last month the Obama administration announced a joint effort between the federal government and major health insurance companies to fight fraud.  According to the New York Times, under the partnership – called the National Fraud Prevention Partnership […]

Share

Continue Reading »

Rigid, Severe Penalties of FCAs On Full Display

Filed in Fraud & Abuse, Health Law by on April 15, 2012 2 Comments
Rigid, Severe Penalties of FCAs On Full Display
Share

News of the $1.2 billion verdict against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals Inc. for their roles in marketing Risperdal during the middle of last decade sent reverberations through the industry earlier this week.  The award resolved Arkansas’ claims that the companies fraudulently marketed the “second generation” antipsychotic, misleading doctors and deceiving the […]

Share

Continue Reading »